APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oral and Injectable Medications for Type 2 Diabetes

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Oral and Injectable Medications for Type 2 Diabetes Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

23 December 2025195 pages

Choose your research edition.

Industry ResearchOral and Injectable Medications for Type 2 Diabetes Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Oral and Injectable Medications for Type 2 Diabetes Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Oral and Injectable Medications for Type 2 Diabetes Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oral and Injectable Medications for Type 2 Diabetes Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Oral and Injectable Medications for Type 2 Diabetes Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Oral and Injectable Medications for Type 2 Diabetes market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Oral and Injectable Medications for Type 2 Diabetes is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oral and Injectable Medications for Type 2 Diabetes is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oral and Injectable Medications for Type 2 Diabetes is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Oral and Injectable Medications for Type 2 Diabetes is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Oral and Injectable Medications for Type 2 Diabetes include United Laboratories, Yiling Pharmaceutical, Takeda, Tonghua Dongbao, Sanofi, Novo Nordisk, Merck, Eli Lilly and Jiangsu Wanbang, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Oral and Injectable Medications for Type 2 Diabetes market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oral and Injectable Medications for Type 2 Diabetes and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oral and Injectable Medications for Type 2 Diabetes sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Oral and Injectable Medications for Type 2 Diabetes market size, projected growth trends, production technologies, key applications, and end-use industries.

Oral and Injectable Medications for Type 2 Diabetes Segment by Company

United Laboratories

Yiling Pharmaceutical

Takeda

Tonghua Dongbao

Sanofi

Novo Nordisk

Merck

Eli Lilly

Jiangsu Wanbang

Jiangsu Hengrui Pharmaceuticals

Pfizer

Beijing Double-Crane Pharmaceutical

Huadong Medicine

Ganli Pharmaceutical

Beijing Beilu Pharmaceutical

bayer

AstraZeneca

Boehringer Ingelheim

Biocon

Oral and Injectable Medications for Type 2 Diabetes Segment by Type

Insulin

Biguanides

Sulfonylureas

SGLT2 Inhibitors

GLP‑1 Receptor Agonists

DPP‑4 Inhibitors

Others

Oral and Injectable Medications for Type 2 Diabetes Segment by Application

Clinic

Hospital

Pharmacy

Others

Oral and Injectable Medications for Type 2 Diabetes Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral and Injectable Medications for Type 2 Diabetes market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oral and Injectable Medications for Type 2 Diabetes and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral and Injectable Medications for Type 2 Diabetes.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Oral and Injectable Medications for Type 2 Diabetes market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Oral and Injectable Medications for Type 2 Diabetes manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Oral and Injectable Medications for Type 2 Diabetes in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Oral and Injectable Medications for Type 2 Diabetes in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Oral and Injectable Medications for Type 2 Diabetes Industry Trends Table 2. Oral and Injectable Medications for Type 2 Diabetes Industry Drivers Table 3. Oral and Injectable Medications for Type 2 Diabetes Industry Opportunities and Challenges Table 4. Oral and Injectable Medications for Type 2 Diabetes Industry Restraints Table 5. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Manufacturers Table 9. Global Oral and Injectable Medications for Type 2 Diabetes Average Sales Price (USD/unit) of Manufacturers (2021-2026) Table 10. Global Oral and Injectable Medications for Type 2 Diabetes Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Oral and Injectable Medications for Type 2 Diabetes Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Oral and Injectable Medications for Type 2 Diabetes Manufacturers, Product Type & Application Table 13. Global Oral and Injectable Medications for Type 2 Diabetes Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Oral and Injectable Medications for Type 2 Diabetes by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Insulin Table 17. Major Manufacturers of Biguanides Table 18. Major Manufacturers of Sulfonylureas Table 19. Major Manufacturers of SGLT2 Inhibitors Table 20. Major Manufacturers of GLP‑1 Receptor Agonists Table 21. Major Manufacturers of DPP‑4 Inhibitors Table 22. Major Manufacturers of Others Table 23. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2026) & (k units) Table 25. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2027-2032) & (k units) Table 26. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Type (2021-2026) Table 27. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Type (2027-2032) Table 28. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 29. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2021-2026) & (k units) Table 30. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2027-2032) & (k units) Table 31. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Type (2021-2026) Table 32. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Type (2027-2032) Table 33. Major Manufacturers of Clinic Table 34. Major Manufacturers of Hospital Table 35. Major Manufacturers of Pharmacy Table 36. Major Manufacturers of Others Table 37. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2026) & (k units) Table 39. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2027-2032) & (k units) Table 40. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Application (2021-2026) Table 41. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Application (2027-2032) Table 42. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 43. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2021-2026) & (k units) Table 44. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2027-2032) & (k units) Table 45. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Application (2021-2026) Table 46. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Application (2027-2032) Table 47. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 48. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region (2021-2026) & (k units) Table 49. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Region (2021-2026) Table 50. Global Oral and Injectable Medications for Type 2 Diabetes Sales Forecasted by Region (2027-2032) & (k units) Table 51. Global Oral and Injectable Medications for Type 2 Diabetes Sales Forecasted Market Share by Region (2027-2032) Table 52. North America Oral and Injectable Medications for Type 2 Diabetes Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. North America Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2026) & (k units) Table 54. North America Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2027-2032) & (k units) Table 55. Europe Oral and Injectable Medications for Type 2 Diabetes Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Europe Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2026) & (k units) Table 57. Europe Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2027-2032) & (k units) Table 58. Asia Pacific Oral and Injectable Medications for Type 2 Diabetes Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 59. Asia Pacific Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2026) & (k units) Table 60. Asia Pacific Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2027-2032) & (k units) Table 61. South America, Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 62. South America, Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2026) & (k units) Table 63. South America, Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2027-2032) & (k units) Table 64. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 65. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Region (2021-2026) & (US$ Million) Table 66. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Region (2027-2032) & (US$ Million) Table 67. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Region (2021-2026) Table 68. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Region (2027-2032) Table 69. United Laboratories Company Information Table 70. United Laboratories Business Overview Table 71. United Laboratories Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. United Laboratories Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 73. United Laboratories Recent Development Table 74. Yiling Pharmaceutical Company Information Table 75. Yiling Pharmaceutical Business Overview Table 76. Yiling Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Yiling Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 78. Yiling Pharmaceutical Recent Development Table 79. Takeda Company Information Table 80. Takeda Business Overview Table 81. Takeda Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Takeda Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 83. Takeda Recent Development Table 84. Tonghua Dongbao Company Information Table 85. Tonghua Dongbao Business Overview Table 86. Tonghua Dongbao Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Tonghua Dongbao Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 88. Tonghua Dongbao Recent Development Table 89. Sanofi Company Information Table 90. Sanofi Business Overview Table 91. Sanofi Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Sanofi Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 93. Sanofi Recent Development Table 94. Novo Nordisk Company Information Table 95. Novo Nordisk Business Overview Table 96. Novo Nordisk Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Novo Nordisk Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 98. Novo Nordisk Recent Development Table 99. Merck Company Information Table 100. Merck Business Overview Table 101. Merck Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Merck Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 103. Merck Recent Development Table 104. Eli Lilly Company Information Table 105. Eli Lilly Business Overview Table 106. Eli Lilly Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Eli Lilly Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 108. Eli Lilly Recent Development Table 109. Jiangsu Wanbang Company Information Table 110. Jiangsu Wanbang Business Overview Table 111. Jiangsu Wanbang Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Jiangsu Wanbang Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 113. Jiangsu Wanbang Recent Development Table 114. Jiangsu Hengrui Pharmaceuticals Company Information Table 115. Jiangsu Hengrui Pharmaceuticals Business Overview Table 116. Jiangsu Hengrui Pharmaceuticals Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Jiangsu Hengrui Pharmaceuticals Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 118. Jiangsu Hengrui Pharmaceuticals Recent Development Table 119. Pfizer Company Information Table 120. Pfizer Business Overview Table 121. Pfizer Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Pfizer Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 123. Pfizer Recent Development Table 124. Beijing Double-Crane Pharmaceutical Company Information Table 125. Beijing Double-Crane Pharmaceutical Business Overview Table 126. Beijing Double-Crane Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Beijing Double-Crane Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 128. Beijing Double-Crane Pharmaceutical Recent Development Table 129. Huadong Medicine Company Information Table 130. Huadong Medicine Business Overview Table 131. Huadong Medicine Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. Huadong Medicine Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 133. Huadong Medicine Recent Development Table 134. Ganli Pharmaceutical Company Information Table 135. Ganli Pharmaceutical Business Overview Table 136. Ganli Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. Ganli Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 138. Ganli Pharmaceutical Recent Development Table 139. Beijing Beilu Pharmaceutical Company Information Table 140. Beijing Beilu Pharmaceutical Business Overview Table 141. Beijing Beilu Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 142. Beijing Beilu Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 143. Beijing Beilu Pharmaceutical Recent Development Table 144. bayer Company Information Table 145. bayer Business Overview Table 146. bayer Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 147. bayer Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 148. bayer Recent Development Table 149. AstraZeneca Company Information Table 150. AstraZeneca Business Overview Table 151. AstraZeneca Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 152. AstraZeneca Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 153. AstraZeneca Recent Development Table 154. Boehringer Ingelheim Company Information Table 155. Boehringer Ingelheim Business Overview Table 156. Boehringer Ingelheim Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 157. Boehringer Ingelheim Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 158. Boehringer Ingelheim Recent Development Table 159. Biocon Company Information Table 160. Biocon Business Overview Table 161. Biocon Oral and Injectable Medications for Type 2 Diabetes Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 162. Biocon Oral and Injectable Medications for Type 2 Diabetes Product Portfolio Table 163. Biocon Recent Development Table 164. Key Raw Materials Table 165. Raw Materials Key Suppliers Table 166. Oral and Injectable Medications for Type 2 Diabetes Distributors List Table 167. Oral and Injectable Medications for Type 2 Diabetes Customers List Table 168. Research Programs/Design for This Report Table 169. Authors List of This Report Table 170. Secondary Sources Table 171. Primary Sources List of Figures Figure 1. Oral and Injectable Medications for Type 2 Diabetes Product Image Figure 2. Global Oral and Injectable Medications for Type 2 Diabetes Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oral and Injectable Medications for Type 2 Diabetes Market Size (2021-2032) & (US$ Million) Figure 4. Global Oral and Injectable Medications for Type 2 Diabetes Sales (2021-2032) & (k units) Figure 5. Global Oral and Injectable Medications for Type 2 Diabetes Average Price (USD/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Oral and Injectable Medications for Type 2 Diabetes Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Insulin Image Figure 9. Biguanides Image Figure 10. Sulfonylureas Image Figure 11. SGLT2 Inhibitors Image Figure 12. GLP‑1 Receptor Agonists Image Figure 13. DPP‑4 Inhibitors Image Figure 14. Others Image Figure 15. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 16. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share 2021 VS 2025 VS 2032 Figure 17. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Type (2021-2032) Figure 18. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 19. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Type (2021-2032) Figure 21. Clinic Image Figure 22. Hospital Image Figure 23. Pharmacy Image Figure 24. Others Image Figure 25. Global Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share 2021 VS 2025 VS 2032 Figure 27. Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Application (2021-2032) Figure 28. Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 29. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share 2021 VS 2025 VS 2032 Figure 30. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Application (2021-2032) Figure 31. North America Oral and Injectable Medications for Type 2 Diabetes Sales and Growth Rate (2021-2032) & (k units) Figure 32. North America Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Country (2021-2032) Figure 33. U.S. Oral and Injectable Medications for Type 2 Diabetes Sales and Growth Rate (2021-2032) & (k units) Figure 34. Canada Oral and Injectable Medications for Type 2 Diabetes Sales and Growth Rate (2021-2032) & (k units) Figure 35. Mexico Oral and Injectable Medications for Type 2 Diabetes Sales and Growth Rate (2021-2032) & (k units) Figure 36. Europe Oral and Injectable Medications for Type 2 Diabetes Sales and Growth Rate (2021-2032) & (k units) Figure 37. Europe Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Country (2021-2032) Figure 38. Germany Oral and Injectable Medications for Type 2 Diabetes Sales and Growth Rate (2021-2032) & (k units) Figure 39. France Oral and Injectable Medications for Type 2 Diabetes Sales and Growth Rate (2021-2032) & (k units) Figure 40. U.K. Oral and Injectable Medications for Type 2 Diabetes Sales and Growth Rate (2021-2032) & (k units) Figure 41. Italy Oral and Injectable Medications for Type 2 Diabetes Sales and Growth Rate (2021-2032) & (k units) Figure 42. Netherlands Oral and Injectable Medications for Type 2 Diabetes Sales and Growth Rate (2021-2032) & (k units) Figure 43. Asia Pacific Oral and Injectable Medications for Type 2 Diabetes Sales and Growth Rate (2021-2032) & (k units) Figure 44. Asia Pacific Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Country (2021-2032) Figure 45. China Oral and Injectable Medications for Type 2 Diabetes Sales and Growth Rate (2021-2032) & (k units) Figure 46. Japan Oral and Injectable Medications for Type 2 Diabetes Sales and Growth Rate (2021-2032) & (k units) Figure 47. South Korea Oral and Injectable Medications for Type 2 Diabetes Sales and Growth Rate (2021-2032) & (k units) Figure 48. Southeast Asia Oral and Injectable Medications for Type 2 Diabetes Sales and Growth Rate (2021-2032) & (k units) Figure 49. India Oral and Injectable Medications for Type 2 Diabetes Sales and Growth Rate (2021-2032) & (k units) Figure 50. Australia Oral and Injectable Medications for Type 2 Diabetes Sales and Growth Rate (2021-2032) & (k units) Figure 51. South America, Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales and Growth Rate (2021-2032) & (k units) Figure 52. South America, Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Country (2021-2032) Figure 53. Brazil Oral and Injectable Medications for Type 2 Diabetes Sales and Growth Rate (2021-2032) & (k units) Figure 54. South Africa Oral and Injectable Medications for Type 2 Diabetes Sales and Growth Rate (2021-2032) & (k units) Figure 55. Saudi Arabia Oral and Injectable Medications for Type 2 Diabetes Sales and Growth Rate (2021-2032) & (k units) Figure 56. Turkey Oral and Injectable Medications for Type 2 Diabetes Sales and Growth Rate (2021-2032) & (k units) Figure 57. Argentina Oral and Injectable Medications for Type 2 Diabetes Sales and Growth Rate (2021-2032) & (k units) Figure 58. UAE Oral and Injectable Medications for Type 2 Diabetes Sales and Growth Rate (2021-2032) & (k units) Figure 59. Egypt Oral and Injectable Medications for Type 2 Diabetes Sales and Growth Rate (2021-2032) & (k units) Figure 60. Chile Oral and Injectable Medications for Type 2 Diabetes Sales and Growth Rate (2021-2032) & (k units) Figure 61. Global Oral and Injectable Medications for Type 2 Diabetes Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 63. North America Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Figure 64. North America Oral and Injectable Medications for Type 2 Diabetes Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Europe Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Figure 66. Europe Oral and Injectable Medications for Type 2 Diabetes Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Figure 68. Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. South America, Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032) & (US$ Million) Figure 70. South America, Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 71. Oral and Injectable Medications for Type 2 Diabetes Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Oral and Injectable Medications for Type 2 Diabetes Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Insulin
  • Biguanides
  • Sulfonylureas
  • SGLT2 Inhibitors
  • GLP‑1 Receptor Agonists
  • DPP‑4 Inhibitors
  • Others
Applications
  • Clinic
  • Hospital
  • Pharmacy
  • Others
Companies covered
  • United Laboratories
  • Yiling Pharmaceutical
  • Takeda
  • Tonghua Dongbao
  • Sanofi
  • Novo Nordisk
  • Merck
  • Eli Lilly
  • Jiangsu Wanbang
  • Jiangsu Hengrui Pharmaceuticals
  • Pfizer
  • Beijing Double-Crane Pharmaceutical
  • Huadong Medicine
  • Ganli Pharmaceutical
  • Beijing Beilu Pharmaceutical
  • bayer
  • AstraZeneca
  • Boehringer Ingelheim
  • Biocon

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Oral and Injectable Medications for Type 2 Diabetes Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Oral and Injectable Medications for Type 2 Diabetes Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Oral and Injectable Medications for Type 2 Diabetes Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Oral and Injectable Medications for Type 2 Diabetes Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Oral and Injectable Medications for Type 2 Diabetes Market Dynamics
  1. 2.1 Oral and Injectable Medications for Type 2 Diabetes Industry Trends
  2. 2.2 Oral and Injectable Medications for Type 2 Diabetes Industry Drivers
  3. 2.3 Oral and Injectable Medications for Type 2 Diabetes Industry Opportunities and Challenges
  4. 2.4 Oral and Injectable Medications for Type 2 Diabetes Industry Restraints
3 Oral and Injectable Medications for Type 2 Diabetes Market by Manufacturers
  1. 3.1 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Manufacturers (2021-2026)
  3. 3.3 Global Oral and Injectable Medications for Type 2 Diabetes Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Oral and Injectable Medications for Type 2 Diabetes Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Oral and Injectable Medications for Type 2 Diabetes Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Oral and Injectable Medications for Type 2 Diabetes Manufacturers, Product Type & Application
  7. 3.7 Global Oral and Injectable Medications for Type 2 Diabetes Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Oral and Injectable Medications for Type 2 Diabetes Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Oral and Injectable Medications for Type 2 Diabetes Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Oral and Injectable Medications for Type 2 Diabetes Tier 1, Tier 2, and Tier 3
4 Oral and Injectable Medications for Type 2 Diabetes Market by Type
  1. 4.1 Oral and Injectable Medications for Type 2 Diabetes Type Introduction
  2. 4.1.1 Insulin
  3. 4.1.2 Biguanides
  4. 4.1.3 Sulfonylureas
  5. 4.1.4 SGLT2 Inhibitors
  6. 4.1.5 GLP‑1 Receptor Agonists
  7. 4.1.6 DPP‑4 Inhibitors
  8. 4.1.7 Others
  9. 4.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Type
  10. 4.2.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Type (2021-2032)
  12. 4.2.3 Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Type (2021-2032)
  13. 4.3 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Type
  14. 4.3.1 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Type (2021-2032)
  16. 4.3.3 Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Type (2021-2032)
5 Oral and Injectable Medications for Type 2 Diabetes Market by Application
  1. 5.1 Oral and Injectable Medications for Type 2 Diabetes Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Pharmacy
  5. 5.1.4 Others
  6. 5.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Application
  7. 5.2.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Application (2021-2032)
  9. 5.2.3 Global Oral and Injectable Medications for Type 2 Diabetes Sales Market Share by Application (2021-2032)
  10. 5.3 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Application
  11. 5.3.1 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Application (2021-2032)
  13. 5.3.3 Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Application (2021-2032)
6 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region
  1. 6.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region (2021-2032)
  3. 6.2.1 Global Oral and Injectable Medications for Type 2 Diabetes Sales by Region (2021-2026)
  4. 6.2.2 Global Oral and Injectable Medications for Type 2 Diabetes Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Oral and Injectable Medications for Type 2 Diabetes Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Oral and Injectable Medications for Type 2 Diabetes Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Oral and Injectable Medications for Type 2 Diabetes Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Region
  1. 7.1 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Region
  2. 7.1.1 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Region (2021-2026)
  4. 7.1.3 Global Oral and Injectable Medications for Type 2 Diabetes Revenue by Region (2027-2032)
  5. 7.1.4 Global Oral and Injectable Medications for Type 2 Diabetes Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032)
  8. 7.2.2 North America Oral and Injectable Medications for Type 2 Diabetes Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032)
  11. 7.3.2 Europe Oral and Injectable Medications for Type 2 Diabetes Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Oral and Injectable Medications for Type 2 Diabetes Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Oral and Injectable Medications for Type 2 Diabetes Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 United Laboratories
  2. 8.1.1 United Laboratories Company Information
  3. 8.1.2 United Laboratories Business Overview
  4. 8.1.3 United Laboratories Oral and Injectable Medications for Type 2 Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 United Laboratories Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  6. 8.1.5 United Laboratories Recent Developments
  7. 8.2 Yiling Pharmaceutical
  8. 8.2.1 Yiling Pharmaceutical Company Information
  9. 8.2.2 Yiling Pharmaceutical Business Overview
  10. 8.2.3 Yiling Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Yiling Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  12. 8.2.5 Yiling Pharmaceutical Recent Developments
  13. 8.3 Takeda
  14. 8.3.1 Takeda Company Information
  15. 8.3.2 Takeda Business Overview
  16. 8.3.3 Takeda Oral and Injectable Medications for Type 2 Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Takeda Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  18. 8.3.5 Takeda Recent Developments
  19. 8.4 Tonghua Dongbao
  20. 8.4.1 Tonghua Dongbao Company Information
  21. 8.4.2 Tonghua Dongbao Business Overview
  22. 8.4.3 Tonghua Dongbao Oral and Injectable Medications for Type 2 Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Tonghua Dongbao Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  24. 8.4.5 Tonghua Dongbao Recent Developments
  25. 8.5 Sanofi
  26. 8.5.1 Sanofi Company Information
  27. 8.5.2 Sanofi Business Overview
  28. 8.5.3 Sanofi Oral and Injectable Medications for Type 2 Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  30. 8.5.5 Sanofi Recent Developments
  31. 8.6 Novo Nordisk
  32. 8.6.1 Novo Nordisk Company Information
  33. 8.6.2 Novo Nordisk Business Overview
  34. 8.6.3 Novo Nordisk Oral and Injectable Medications for Type 2 Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novo Nordisk Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  36. 8.6.5 Novo Nordisk Recent Developments
  37. 8.7 Merck
  38. 8.7.1 Merck Company Information
  39. 8.7.2 Merck Business Overview
  40. 8.7.3 Merck Oral and Injectable Medications for Type 2 Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Merck Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  42. 8.7.5 Merck Recent Developments
  43. 8.8 Eli Lilly
  44. 8.8.1 Eli Lilly Company Information
  45. 8.8.2 Eli Lilly Business Overview
  46. 8.8.3 Eli Lilly Oral and Injectable Medications for Type 2 Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  48. 8.8.5 Eli Lilly Recent Developments
  49. 8.9 Jiangsu Wanbang
  50. 8.9.1 Jiangsu Wanbang Company Information
  51. 8.9.2 Jiangsu Wanbang Business Overview
  52. 8.9.3 Jiangsu Wanbang Oral and Injectable Medications for Type 2 Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Jiangsu Wanbang Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  54. 8.9.5 Jiangsu Wanbang Recent Developments
  55. 8.10 Jiangsu Hengrui Pharmaceuticals
  56. 8.10.1 Jiangsu Hengrui Pharmaceuticals Company Information
  57. 8.10.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  58. 8.10.3 Jiangsu Hengrui Pharmaceuticals Oral and Injectable Medications for Type 2 Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Jiangsu Hengrui Pharmaceuticals Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  60. 8.10.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  61. 8.11 Pfizer
  62. 8.11.1 Pfizer Company Information
  63. 8.11.2 Pfizer Business Overview
  64. 8.11.3 Pfizer Oral and Injectable Medications for Type 2 Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Pfizer Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  66. 8.11.5 Pfizer Recent Developments
  67. 8.12 Beijing Double-Crane Pharmaceutical
  68. 8.12.1 Beijing Double-Crane Pharmaceutical Company Information
  69. 8.12.2 Beijing Double-Crane Pharmaceutical Business Overview
  70. 8.12.3 Beijing Double-Crane Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Beijing Double-Crane Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  72. 8.12.5 Beijing Double-Crane Pharmaceutical Recent Developments
  73. 8.13 Huadong Medicine
  74. 8.13.1 Huadong Medicine Company Information
  75. 8.13.2 Huadong Medicine Business Overview
  76. 8.13.3 Huadong Medicine Oral and Injectable Medications for Type 2 Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Huadong Medicine Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  78. 8.13.5 Huadong Medicine Recent Developments
  79. 8.14 Ganli Pharmaceutical
  80. 8.14.1 Ganli Pharmaceutical Company Information
  81. 8.14.2 Ganli Pharmaceutical Business Overview
  82. 8.14.3 Ganli Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Ganli Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  84. 8.14.5 Ganli Pharmaceutical Recent Developments
  85. 8.15 Beijing Beilu Pharmaceutical
  86. 8.15.1 Beijing Beilu Pharmaceutical Company Information
  87. 8.15.2 Beijing Beilu Pharmaceutical Business Overview
  88. 8.15.3 Beijing Beilu Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Beijing Beilu Pharmaceutical Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  90. 8.15.5 Beijing Beilu Pharmaceutical Recent Developments
  91. 8.16 bayer
  92. 8.16.1 bayer Company Information
  93. 8.16.2 bayer Business Overview
  94. 8.16.3 bayer Oral and Injectable Medications for Type 2 Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 bayer Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  96. 8.16.5 bayer Recent Developments
  97. 8.17 AstraZeneca
  98. 8.17.1 AstraZeneca Company Information
  99. 8.17.2 AstraZeneca Business Overview
  100. 8.17.3 AstraZeneca Oral and Injectable Medications for Type 2 Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 AstraZeneca Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  102. 8.17.5 AstraZeneca Recent Developments
  103. 8.18 Boehringer Ingelheim
  104. 8.18.1 Boehringer Ingelheim Company Information
  105. 8.18.2 Boehringer Ingelheim Business Overview
  106. 8.18.3 Boehringer Ingelheim Oral and Injectable Medications for Type 2 Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Boehringer Ingelheim Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  108. 8.18.5 Boehringer Ingelheim Recent Developments
  109. 8.19 Biocon
  110. 8.19.1 Biocon Company Information
  111. 8.19.2 Biocon Business Overview
  112. 8.19.3 Biocon Oral and Injectable Medications for Type 2 Diabetes Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Biocon Oral and Injectable Medications for Type 2 Diabetes Product Portfolio
  114. 8.19.5 Biocon Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Oral and Injectable Medications for Type 2 Diabetes Value Chain Analysis
  2. 9.1.1 Oral and Injectable Medications for Type 2 Diabetes Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Oral and Injectable Medications for Type 2 Diabetes Production Mode & Process
  6. 9.2 Oral and Injectable Medications for Type 2 Diabetes Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Oral and Injectable Medications for Type 2 Diabetes Distributors
  9. 9.2.3 Oral and Injectable Medications for Type 2 Diabetes Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst